Back
Natera, Inc. (NTRA)
BiotechnologyNTRA · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$274.39
−2.45%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-1.52
ROE
-15.0%
Gross margin
65.1%
Debt/Equity
0.14x
Revenue growth
38.8%
Natera, Inc. — company intelligence
Earnings surprises
Q1 2026$-0.60 vs $-0.55 est-9.7%
Q4 2025$0.36 vs $-0.52 est+169.1%
Q3 2025$-0.64 vs $-0.38 est-68.2%
Q2 2025$-0.74 vs $-0.63 est-17.8%
Insider activity · 90 days
2 buys112 sellsnet -325,911 shares
Moshkevich SolomonSell 300 · Jul 1, 2026
RABINOWITZ DANIELSell 3,705 · Jul 1, 2026
RABINOWITZ DANIELSell 2,045 · Jul 1, 2026
Recent SEC filings
4 — Insider transaction reportJul 8, 2026
4 — Insider transaction reportJul 6, 2026
4 — Insider transaction reportJul 6, 2026
Latest news
Evercore ISI Group Maintains Outperform on Natera, Raises Price Target to $300 — Benzinga · 4d ago
Natera Publishes New Data On Signatera Test In Colon Cancer Study, Test Helps Identify Colon Cancer Patients Who May Benefit From Chemo — Benzinga · 5d ago
Guggenheim Maintains Buy on Natera, Raises Price Target to $290 — Benzinga · 1w ago
Natera Partners With Aveta On Late-Stage Head And Neck Cancer Trial — Benzinga · 1w ago
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise — SeekingAlpha · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Natera, Inc.
Weekly undervalued picks (like NTRA)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.